[{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Acetovanillone","moa":"||NFkB\/Nrf2||NFkB\/Nrf2||NFkB\/Nrf2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AKL Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Paeonol

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Florida Innovation
                          Not Confirmed
                          Florida Innovation
                          Not Confirmed

                          Details : Results from the study, conducted by Instituto de Investigación Biomedica da Coruña, Spain, found that APPA, an NRf2 and NFkB regulator, has a clear anti-inflammatory effect on human articular chondrocytes, and could reduce extracellular matrix degrada...

                          Product Name : APPA

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 02, 2021

                          Lead Product(s) : APPA,CAS 498-02-2,Paeonol

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank